Brevan Howard Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Brevan Howard Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	24,659 +12,363	+101%	+$112K	﹤0.01%	1816
2026 Q1	$104K	Sell	12,296 -293,519	-96%	-$2.8M	﹤0.01%	2013
2025 Q4	$3.71M	Buy	305,815 +195,870	+178%	+$2.38M	0.04%	306
2025 Q3	$1.29M	Buy	109,945 +77,617	+240%	+$928K	0.01%	789
2025 Q2	$300K	Buy	+32,328	New	+$253K	﹤0.01%	1551
2025 Q1	–	Sell	-24,078	Closed	-$206K	–	1373
2024 Q4	$206K	Buy	+24,078	New	+$235K	﹤0.01%	906
2024 Q1	–	Sell	-20,121	Closed	-$89.7K	–	1250
2023 Q4	$89.7K	Buy	+20,121	New	+$59.5K	﹤0.01%	970

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brevan Howard Capital Management's OCUL Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Ocular Therapeutix (OCUL) stake by 101% in Q2 2026, buying an estimated $112K and bringing the position to 24,659 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Brevan Howard Capital Management first reported a position in OCUL in Q4 2023 and has held it in 7 quarters since. The position peaked at $3.71M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Brevan Howard Capital Management held 24,659 shares of Ocular Therapeutix worth $242K as of Q2 2026.
Brevan Howard Capital Management bought 12,363 Ocular Therapeutix shares in Q2 2026, an estimated $112K.
Ocular Therapeutix made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1816 holding.
Brevan Howard Capital Management first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 7 quarters since.
Brevan Howard Capital Management's Ocular Therapeutix position peaked at $3.71M in Q4 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.